Pharmacyclics (PCYC) Likely to See Upside Near-Term, Says RBC

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Pharmacyclics (PCYC) Likely to See Upside Near-Term, Says RBC

Roth Remains Positive on Pharmacyclics (PCYC) Following Imbruvica Update; Maintains 'Buy' Rating

January 14, 2015 7:52 AM EST

Roth Capital affirms Pharmacyclics (Nasdaq: PCYC) at Buy with a price target of $188 following an impressive update on... More

Baird Increasingly Bullish on Pharmacyclics (PCYC); Top Pick for 2015

January 13, 2015 8:04 AM EST

Baird analyst Brian Skorney reiterated an Outperform rating and $173 price target on Pharmacyclics (NASDAQ: PCYC) saying he is increasingly bullish on Imbruvica performance and 2015 guidance.

Skorney commented, "As one of our top picks for 2015, we anticipated that Pharmacyclics would continue to deliver on the... More

Pharmacyclics (PCYC) Sees FY15 Net Product Revenue of $1B for IMBRUVICA

January 12, 2015 5:46 PM EST

Pharmacyclics, Inc. (NASDAQ: PCYC) today provided its preliminary unaudited 2014 U.S. net product revenue results and 2015 U.S. net product revenue outlook at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. For the fiscal year ended December 31, 2014, U.S. net product revenue for IMBRUVICA® (ibrutinib) is expected to be approximately $492 million. For the fourth quarter of 2014,... More